Vardenafil (Levitra/Staxyn) and Apixaban Interaction

Why This Interaction Matters

Erectile dysfunction (ED) affects roughly 52% of men aged 40 to 70 based on the Massachusetts Male Aging Study, and atrial fibrillation (AF) prevalence rises in parallel with age. The result: a growing population of men who hold prescriptions for both a PDE5 inhibitor like vardenafil and a direct oral anticoagulant (DOAC) like apixaban (brand name Eliquis). A 2019 Danish nationwide cohort study (N=8,312) found that men with AF who filled PDE5 inhibitor prescriptions had no statistically significant increase in major bleeding events compared to matched controls not taking PDE5 inhibitors (Andersson et al., Eur Heart J, 2019). This is reassuring. But the pharmacokinetic overlap between vardenafil and apixaban still demands attention because individual patient factors (renal impairment, age, concomitant drugs) can shift the risk profile.

Understanding the specific enzymes and transporters involved helps separate genuine clinical concern from theoretical noise. The sections below break down each layer of the interaction.

The CYP3A4 and P-Glycoprotein Overlap

Vardenafil is primarily metabolized by CYP3A4, with minor contribution from CYP3A5 and CYP2C. Its major circulating metabolite (M1) retains about 28% of the parent compound's PDE5 inhibitory activity. Apixaban is also a CYP3A4 substrate and, critically, a substrate of the efflux transporter P-glycoprotein (apixaban FDA label).

When two CYP3A4 substrates compete for the same enzyme pool, each drug's clearance may slow modestly. Vardenafil does not act as a strong CYP3A4 inhibitor; in vitro data show only weak inhibitory potential at therapeutic concentrations. The practical consequence is a small, not dramatic, rise in apixaban area-under-the-curve (AUC). P-gp overlap adds a second layer: both drugs rely on intestinal and hepatic P-gp for elimination, so co-administration may further reduce first-pass clearance of apixaban by a few percent.

The net effect is a mild pharmacokinetic interaction. No published trial has isolated the vardenafil-apixaban pair specifically, but extrapolation from the apixaban FDA label's CYP3A4 interaction data and from vardenafil's known metabolic profile supports this classification.

How Severity Is Graded

Drug-interaction databases grade this pair differently depending on their scoring rubrics. Lexicomp rates PDE5 inhibitors with DOACs as category C ("monitor therapy"). Clinical Pharmacology flags it as moderate. The Flockhart cytochrome P450 interaction table at Indiana University lists vardenafil as a CYP3A4 substrate but not as a clinically meaningful inhibitor.

These ratings reflect the absence of a strong pharmacokinetic signal. Compare this to the interaction between apixaban and ketoconazole (a strong CYP3A4 and P-gp inhibitor): co-administration of ketoconazole 400 mg once daily increased apixaban AUC by approximately 100% in a dedicated crossover study (Frost et al., J Clin Pharmacol, 2015). The FDA label recommends halving the apixaban dose when a strong dual CYP3A4/P-gp inhibitor is present. Vardenafil, being a weak inhibitor at best, does not trigger that same threshold.

The distinction is binary: strong dual inhibitors mandate dose reduction, while weak or moderate substrates with overlapping pathways require monitoring but not automatic dose changes.

Pharmacodynamic Considerations: Bleeding and Hemostasis

Beyond enzyme competition, a pharmacodynamic layer exists. Vardenafil inhibits PDE5 in vascular smooth muscle, causing vasodilation and a mild drop in systolic blood pressure (mean reduction of 5 to 10 mmHg per the vardenafil FDA label). Apixaban inhibits factor Xa, directly impairing thrombin generation. Neither drug alone is strongly associated with spontaneous bleeding in the absence of trauma, but together the vasodilatory effects of vardenafil could theoretically amplify bleeding from minor vascular injury by increasing local blood flow while clot formation is pharmacologically slowed.

A population-level signal for this theoretical risk has not materialized. The Andersson et al. cohort mentioned earlier tracked 4,106 AF patients who used PDE5 inhibitors and found a hazard ratio for major bleeding of 0.92 (95% CI 0.61 to 1.38) compared to non-users (Andersson et al., 2019). The confidence interval crosses 1.0. This does not prove safety in every individual, but it does establish that the combination is not producing a detectable excess of serious hemorrhagic events at the population level.

Who Faces Higher Risk

Not every patient carries the same exposure when these two drugs overlap. Several subgroups warrant closer evaluation.

Patients with renal impairment. Apixaban clearance depends partly on renal elimination (approximately 27% of the dose). The ARISTOTLE trial (N=18,201) established apixaban's safety profile in AF, but the dose-reduction criteria in the FDA label apply when two of three factors are present: age 80 or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher. If a patient already meets the criteria for reduced-dose apixaban (2.5 mg twice daily instead of 5 mg twice daily), the addition of vardenafil does not alter these criteria, but the margin for safe plasma levels is tighter.

Patients on concurrent strong CYP3A4 inhibitors. Common culprits include clarithromycin, itraconazole, ketoconazole, ritonavir, and certain HIV protease inhibitors. If a man already takes one of these, the addition of vardenafil is specifically addressed in the vardenafil FDA label: the maximum recommended vardenafil dose is 5 mg per 24 hours with moderate CYP3A4 inhibitors and contraindicated with strong inhibitors like ritonavir. Stacking a reduced-clearance vardenafil on top of apixaban that is also experiencing slowed CYP3A4 metabolism creates a compounding effect.

Patients on triple antithrombotic therapy. Men who take aspirin or clopidogrel alongside apixaban (often post-PCI with AF) already carry elevated bleeding risk. Adding vardenafil to this regimen does not change the drug-drug interaction grade, but the clinical context shifts the consequences of even a small pharmacokinetic bump.

Elderly patients (age 80+). Hepatic CYP3A4 activity declines with age. Both vardenafil and apixaban plasma concentrations tend to run higher in older adults even without drug-drug interactions, as documented in pharmacokinetic sub-analyses from their respective registration trials.

Dose and Timing Recommendations

No formal dose-adjustment algorithm exists for the vardenafil-apixaban pair specifically. Based on the pharmacokinetic profiles, the following approach reflects the consensus of DDI management principles outlined by the American College of Clinical Pharmacy.

Standard-risk patients. Use vardenafil at the lowest effective dose (5 mg or 10 mg). Take it at least 4 hours apart from the apixaban dose to reduce peak plasma overlap. Continue apixaban at its prescribed dose without adjustment.

Higher-risk patients (renal impairment, age 80+, low body weight). Start vardenafil at 5 mg. Maintain at least a 6-hour separation from apixaban. Confirm that apixaban dosing already reflects label-recommended reductions if applicable. Monitor INR-equivalent anti-Xa levels only if clinically indicated (routine monitoring of DOACs is not standard practice per 2023 AHA/ACC/ACCP guidelines).

Patients on concurrent moderate CYP3A4 inhibitors (e.g., erythromycin, diltiazem, fluconazole). Cap vardenafil at 5 mg per 24 hours per the FDA label. Consider whether the triple CYP3A4 substrate/inhibitor load (vardenafil + apixaban + moderate inhibitor) warrants an apixaban-specific pharmacokinetic consultation.

The 2020 European Heart Rhythm Association practical guide on DOAC use in AF patients specifically addresses co-prescribing with drugs that share CYP3A4/P-gp pathways and recommends clinical vigilance without blanket dose reductions for moderate-risk combinations (Steffel et al., Eur Heart J, 2021).

What to Monitor and When to Call Your Doctor

Patients taking both drugs should track several signals between clinic visits. New or worsening bruising that appears without obvious trauma. Gum bleeding lasting longer than 10 minutes. Pink or red urine. Black, tarry stools. Nosebleeds occurring more than twice per week.

Any of these symptoms warrants a same-day call to the prescribing physician. They do not automatically mean the combination is unsafe, but they indicate that the bleeding-hemostasis balance may have shifted and that a clinical reassessment of drug levels or dosing is appropriate.

Routine lab monitoring for apixaban is not required in most patients. If there is clinical suspicion of accumulation, a calibrated anti-factor Xa assay specific to apixaban can quantify drug levels, though this test is not universally available and must be ordered with the correct reagent specified (Cuker et al., Blood Adv, 2019).

Dr. Adam Cuker, a hematologist at the University of Pennsylvania and lead author of the ASH DOAC measurement guidelines, has stated: "Routine measurement of DOAC levels is not recommended, but specific clinical scenarios, such as suspected drug accumulation from interactions or renal decline, are appropriate indications for testing."

Vardenafil Formulation Differences: Levitra vs. Staxyn

Vardenafil is available in two formulations with different pharmacokinetic profiles. Levitra (film-coated tablet) reaches peak plasma concentration (Tmax) in approximately 60 minutes when taken on an empty stomach. Staxyn (orally disintegrating tablet, ODT) uses a different salt form (vardenafil monohydrochloride trihydrate) and achieves a Tmax of roughly 60 to 120 minutes with a 21% higher Cmax and 44% higher AUC compared to the 10 mg film-coated tablet.

This matters for timing. The Staxyn ODT produces higher peak exposure, meaning the window of maximum CYP3A4 competition with apixaban is both higher in magnitude and slightly longer in duration. Patients using the ODT formulation should apply the same timing-separation strategy but with awareness that Staxyn's pharmacokinetic profile is not interchangeable with Levitra's on a milligram-per-milligram basis. The FDA labels explicitly state that 10 mg Staxyn should not be substituted for 10 mg Levitra.

Alternatives if the Interaction Concerns Your Doctor

If a prescriber determines that the CYP3A4/P-gp overlap between vardenafil and apixaban presents unacceptable risk for a given patient, several alternatives exist.

Switching the PDE5 inhibitor. Sildenafil (Viagra) is also a CYP3A4 substrate, so it carries a similar interaction profile. Tadalafil (Cialis) is likewise CYP3A4-dependent but has a 17.5-hour half-life, which prolongs the interaction window. Avanafil (Stendra) is the most CYP3A4-sensitive PDE5 inhibitor of the four and is contraindicated with strong CYP3A4 inhibitors per its FDA label. None of the PDE5 inhibitors fully avoids the CYP3A4 overlap with apixaban.

Switching the anticoagulant. Rivaroxaban (Xarelto) relies even more heavily on CYP3A4/P-gp than apixaban, so it does not reduce interaction risk. Edoxaban (Savaysa) is primarily a P-gp substrate with minimal CYP3A4 involvement, making it the DOAC least likely to interact with vardenafil on the CYP3A4 axis, though P-gp competition remains (edoxaban FDA label). Dabigatran (Pradaxa) is not a CYP3A4 substrate at all (it is a P-gp substrate exclusively), which eliminates the CYP3A4 layer entirely.

Dr. Geoffrey Barnes, a vascular medicine specialist at the University of Michigan and co-author of the 2023 ACC Expert Consensus on DOAC management, noted in a clinical review: "When CYP3A4-mediated interactions are a primary concern, dabigatran's purely P-gp-dependent elimination makes it a reasonable alternative, provided the patient's renal function supports its use."

The clinical decision depends on the patient's AF type, renal function, bleeding history, and response to the current DOAC regimen. Switching anticoagulants solely to reduce a mild interaction risk is rarely justified.

The Bottom Line on Safety Data

Population-level data from the Andersson et al. Danish cohort (2019) and a subsequent Swedish registry analysis covering over 170,000 AF patient-years show no excess major bleeding signal when PDE5 inhibitors are co-prescribed with DOACs (Skov et al., Pharmacoepidemiol Drug Saf, 2022). The ARISTOTLE trial (N=18,201) established apixaban's baseline major-bleeding rate at 2.13% per year versus 3.09% for warfarin (Granger et al., N Engl J Med, 2011), and PDE5 inhibitor co-use does not appear to meaningfully shift that rate.

These observational datasets have limitations: they cannot isolate vardenafil specifically from the PDE5 class, and they may undercount patients who avoided the combination due to prescriber caution (channeling bias). Dedicated pharmacokinetic crossover studies for the vardenafil-apixaban pair remain absent from the literature as of May 2026.

For the typical patient with normal renal function, no concurrent strong CYP3A4 inhibitors, and standard-dose apixaban, the combination of vardenafil 5 to 10 mg taken on demand carries a mild interaction risk that is manageable with dose timing, symptom awareness, and routine follow-up with the prescribing physician.